Martin R Jakobsen

Summary

Affiliation: Macfarlane Burnet Institute for Medical Research and Public Health
Country: Australia

Publications

  1. ncbi Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 50:566-73. 2010
  2. ncbi Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 46:e88-91. 2008

Detail Information

Publications2

  1. ncbi Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 50:566-73. 2010
    ....
  2. ncbi Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient
    Martin R Jakobsen
    Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
    Clin Infect Dis 46:e88-91. 2008
    ..After 26 weeks of entecavir therapy, the M184V mutation dominated the plasma viral population. Thus, entecavir should only be used for coinfected patients who simultaneously receive suppressive therapy against HIV infection...